

### Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	59464.62	634.20	1.06
Nifty	17757.00	181.40	1.01

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	34715.39	313.26	0.89
NASDAQ COM.	14154.02	186.23	1.30
FTSE 100	7585.01	4.65	0.06
CAC 40	7194.16	21.18	0.30
DAX	15912.33	102.61	0.65
NIKKEI 225	27254.52	520.19	1.87
SHANGHAI	3538.51	16.62	0.47
HANG SENG	24844.73	122.53	0.49

Currency	Close	Net Chng.	Chng. (%)
USD / INR	74.51	0.08	0.11
USD / EUR	1.13	0.00	0.09
USD / GBP	1.36	0.00	0.22
USD / JPY	113.89	0.24	0.21

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1838.68	0.68	0.04
Silver	24.38	0.35	1.40

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	83.23	2.32	2.71
Brent Crude	86.13	2.26	2.56
Natural Gas	3.86	0.06	1.55

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	6.61	0.01	0.20

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	61.44	0.91	1.46
HDFC Bank	69.58	0.57	0.81
ICICI Bank	21.51	0.08	0.37
Infosys Ltd	23.68	0.79	3.23
Tata Motors	34.03	0.27	0.79
Wipro	8.09	0.15	1.82

### Institutional Flow (In Crore) 20-01-2022

Institution	Purchase	Sale	Net
FII	7974.39	12654.23	4679.84
DII	6385.75	5616.49	769.26

### Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

### Top News for Today

- **Aditya Birla Sun Life:** The company has received approval from International Financial Services Centres Authority to carry out Portfolio Management Services from GIFT City, Gandhinagar.
- **Surya Roshni:** The company has secured orders of Rs 65.40 crore for supply of ERW Line Pipe for gas projects to ONGC and Rs 57.77 crore for supply of MS (Make: Surya) Bare Pipes 3 LPE Coated for Water Supply Project from Chambal-Bhilwara WSP (Phase-I) through Vishnu Prakash R Punglia.
- **Ultratech:** The company has executed a share purchase agreement for acquiring 100% equity shares in National Limestone Company.
- **PNB Housing Finance:** Kapish Jain, Chief Financial Officer of the company has tendered his resignation.
- **Automotive Axles:** The company would be investing in equity shares of Suryaurja One.
- **Fedex Securities:** The company announced an open offer of upto 5,58,373 shares of face value Rs 10 each, representing 16.34% of the voting share capital.
- **Natco Pharma:** Pact with Medicines Patent Pool, Switzerland to make and sell Molnupiravir capsules.

### Events of the Day

- **Result for today:** Reliance Industries, JSW Steel, HDFC Life Insurance Company, SBI Life Insurance Company, Hindustan Zinc, IDBI Bank, Bandhan Bank, Gland Pharma, L&T Finance Holdings, Vodafone Idea, PNB Gilts, Polycab India, Tanla Platforms, CSB Bank, PVR, Inox Leisure, Kajaria Ceramics, Jyothy Labs, Heritage Foods, RattanIndia Power, Gokaldas Exports, Kabra Extrusiontechnik, Max Ventures and Industries, Oriental Aromatics, Ramco Industries, Share India Securities, Supreme Petrochem, Supriya Lifescience, Wendt (India)
- **Concall for today:** 9:00 AM Biocon, 9:00 AM Mphasis, 9:30 AM Shoppers Stop, 9:30 AM Orient Electric, 10:30 AM Havells India, 11:00 AM South Indian Bank, 11:00 AM Shoppers Stop, 11:30 AM Cont Corp, 2:00 PM Phillips Carbon Black, 2:00 PM Hi Tech Pipes, 2:00 PM Agro Tech Foods, 2:45 PM HDFC life Insurance, 3:00 PM Bajaj Finserv, 4:00 PM DCM Shriram, 4:00 PM PVR, 4:00 PM Datamatics Glob, 4:00 PM Kajaria Ceramic, 4:00 PM Polycab India, 4:00 PM Supriya Life, 4:00 PM HindZinc, 4:15 PM SBI Life Insurance, 4:30 PM Jyothy Labs, 5:00 PM IDBI Bank, 5:00 PM INOX Leisure, 5:30 PM JSW Steel, 5:30 PM Persistent, 6:30 PM Gland Pharma
- **Edelweiss Finance:** to consider raising funds via bonds
- **Reliance Jio Infocomm:** to consider bonds issue
- **Marico:** To meet investors and analysts on Jan. 28.
- **Godrej Consumer:** To meet investors and analysts on Feb. 8.
- **Aditya Birla Capital:** To meet investors and analysts on Jan. 25.
- **Escorts:** To meet investors and analysts on Feb. 8.
- **Multi Commodity Exchange of India:** To meet investors and analysts Jan. 31.
- **United Spirits:** To meet investors and analysts on Jan. 27.
- **Motilal Oswal:** To meet investors and analysts on Jan. 28.
- **Nava Bharat Ventures:** To meet investors and analysts on Jan. 28.

## Market in Detailed (Updated at 8AM)

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59464.62	634.20	1.06	2.89	5.59	2.39	19.83
Nifty	17757.00	181.40	1.01	2.74	5.88	2.32	21.70
BSE M Cap	25464.31	17.87	0.07	2.16	5.92	1.37	34.11
BSE S Cap	30565.63	14.48	0.05	0.75	9.68	6.57	64.20
Nifty MC 100	31312.05	51.25	0.16	2.14	7.20	0.14	42.80
BSE Auto	26155.59	212.02	0.80	0.88	10.25	1.20	11.98
BSE Capgoods	30435.86	121.43	0.40	0.01	10.45	12.44	50.50
BSE FMCG	13566.45	137.55	1.00	3.21	1.83	6.35	6.89
BSE Metal	20215.76	82.23	0.41	0.96	6.30	3.49	68.49
BSE Oil&Gas	18826.30	142.96	0.75	0.39	10.06	0.17	27.74
BSE Healthcare	24784.85	277.94	1.11	4.29	1.03	2.71	14.83
BSE Power	3983.21	50.94	1.30	4.01	14.80	14.18	88.12
BSE Realty	3990.50	10.40	0.26	0.17	9.29	0.18	52.85
BSE ConsDur	45224.54	363.55	0.80	1.26	6.83	4.13	43.62
BSE Bank	43276.73	192.01	0.44	1.47	10.08	5.44	18.61
BSE IT	36512.08	627.55	1.69	4.12	1.71	4.20	38.28

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1838.68	0.68	0.04	1.14	2.76	3.12	1.68
Silver(\$/Ounce)	24.37	0.11	0.44	6.10	8.20	0.86	6.06
Aluminium	3132.00	74.00	2.42	6.54	18.28	2.54	58.23
Copper	10018.25	154.25	1.56	0.46	5.87	4.42	24.60
Zinc	3676.00	74.00	2.05	2.63	8.95	2.21	35.97
Lead	2354.00	14.44	0.61	0.80	1.92	4.06	16.22

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.51	0.08	0.11	0.84	1.89	0.49	1.99
USD Index	95.74	0.00	0.00	1.00	0.78	2.10	6.22
YUAN	6.34	0.00	0.04	0.14	0.44	0.78	1.86
GBP	1.36	0.00	0.02	0.57	2.53	1.42	0.99
EUR	1.13	0.00	0.04	0.82	0.28	2.63	6.96
YEN	113.89	0.22	0.19	0.26	0.18	0.09	9.12

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	243.65	0.80	0.33	1.16	8.72	16.94	80.68
Cotton	122.87	1.08	0.87	4.45	16.42	13.11	57.08
Sugar	18.93	0.14	0.73	3.22	1.83	0.21	27.82
Wheat	783.25	7.00	0.89	4.89	1.97	3.95	18.94
Soybean	1409.50	16.25	1.14	2.34	7.37	13.35	24.65

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34715.39	313.26	0.89	4.34	2.19	2.49	11.35
Nasdaq	14154.02	186.23	1.30	6.81	7.74	6.98	4.61
S&P 500	4482.73	50.03	1.10	5.15	3.58	1.47	16.34
FTSE100	7585.01	4.65	0.06	0.28	3.94	5.49	12.95
CAC40	7194.16	21.18	0.30	0.10	3.29	7.60	28.68
DAX	15912.33	102.61	0.65	0.74	3.01	2.84	14.42
Mexico IPC	52508.35	314.88	0.60	2.64	0.81	0.94	17.18
Brazil Bovespa	109102.0	1088.50	1.01	3.39	3.41	1.27	7.80
Russian RTS	1450.59	35.91	2.54	4.38	7.81	22.35	0.91
Japan Nikkei	27254.52	520.19	1.87	3.10	4.44	5.07	5.23
Hang Seng	24844.73	122.53	0.49	1.83	8.09	4.57	17.03
Taiwan Index	17968.52	255.70	1.40	2.39	0.97	6.35	11.20
Shanghai Comp	3538.51	16.62	0.47	0.49	2.39	1.57	2.29
KOSPI	2842.54	19.24	0.67	2.69	4.42	5.45	10.04
Malaysia KLCI	1525.41	2.34	0.15	2.81	2.20	4.16	4.35
Jakarta Comp	6610.73	16.39	0.25	1.24	0.86	0.34	3.07
Philippine SE	7218.16	21.12	0.29	0.59	0.71	1.28	1.09
Thai Exch	1656.96	1.28	0.08	1.37	2.14	0.82	9.48

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1474.00	96.00	6.11	21.30	35.75	68.32	19.76
Baltic Dirty	691.00	1.00	0.14	1.00	13.73	8.48	36.83
SG Dubai HY	7.13	0.63	8.12	14.63	5.32	17.46	499.16

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	83.23	2.32	2.71	1.35	17.03	0.88	56.65
BRENT Crude	86.13	2.26	2.56	0.07	16.44	4.82	62.00
Natural Gas	3.86	0.06	1.55	9.58	2.31	28.17	29.13

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.78	0.03	1.48	0.38	21.59	4.48	60.73
UK	1.23	0.03	2.47	10.86	58.68	6.71	306.98
Brazil	4.85	0.03	0.61	0.56	4.05	7.34	36.35
Japan	0.13	0.02	11.57	9.09	145.28	42.86	202.33
Australia	1.92	0.08	3.91	3.46	19.76	6.98	79.64
India	6.61	0.01	0.20	0.49	2.78	3.77	11.80
Switzerland	0.04	0.02	26.32	1500.00	114.00	154.55	109.17
Germany	0.02	0.01	100.00	73.33	93.44	80.95	95.46

**Taking global cues, the Nifty is expected to open flat around 17700 and likely to remain range-bound in the price band of 17600-17900.**

The Nifty previous session ended 1.01% down at 17757.00. It opened on a flat note and got sold off towards ending with another bearish candle. Ending with a bearish body candle for the third consecutive session suggesting range-bound oscillation in the price band of 17600-17900 with a negative bias.

On the Nifty hourly chart, oversold leading indicators suggesting range-bound oscillation in the price band of 17600-17900.

Nifty patterns on multiple periods suggest; ending the day below 17900 suggesting range-bound oscillation in the price band of 17600-17900. Staying cautious on rise around 17900 is advised.

The Bank Nifty previous session ended 0.50% down at 37850.85. It might get into the trading range of 37700-39100.

The Financial Nifty Fut trading range is likely to be 18000-18800.

**Nifty Crucial Supports & Resistances-**

**Supports- 17700, 17600 Resistances- 17900, 18000**

**Open Positional Calls-**

T+10 INST POSITIONAL BUY

|Cash Segment| IPCA LAB @ 1080-1075, TGT- 1135, SL- closing below 1045

T+10 INST POSITIONAL BUY-

|Cash Segment| BHARTI AIRTEL @ 725-720, TGT- 770, SL- closing below 695

T+14 INST POSITIONAL BUY-

|Cash Segment| WIPRO @ 640-630, TGT- 690, SL- closing below 600

T+3 Positional Sell-

|Futures Segment| MANAPPURAM Fut @ 166-167, TGT- 157, Closing SL- above 172

T+1 BUY-

|Cash Segment| BHARTI AIRTEL @ 715-714, TGT- 728, SL- closing below 707

- **PTC India:** On the issue of corporate governance raised by three independent directors in their resignation letters, the company said that the management is closely monitoring the situation and observed that there are difference of opinion at operation and board level on few issues. These issues are being looked into by a senior level committee of the company.
- **Aditya Birla Sun Life:** The company has received approval from International Financial Services Centres Authority to carry out Portfolio Management Services from GIFT City, Gandhinagar.
- **Surya Roshni:** The company has secured orders of Rs 65.40 crore for supply of ERW Line Pipe for gas projects to ONGC and Rs 57.77 crore for supply of MS (Make: Surya) Bare Pipes 3 LPE Coated for Water Supply Project from Chambal- Bhilwara WSP (Phase-I) through Vishnu Prakash R Punglia.
- **Ultratech:** The company has executed a share purchase agreement for acquiring 100% equity shares in National Limestone Company.
- **PNB Housing Finance:** Kapish Jain, Chief Financial Officer of the company has tendered his resignation.
- **Shalby:** The company's wholly-owned subsidiary Mars Medical Devices has invested \$1 million in Shalby Advanced Technologies Inc, a wholly owned subsidiary of Mars Medical Devices and a step-down subsidiary of the company.
- **Automotive Axles:** The company would be investing in equity shares of Suryaurja One.
- **Fermenta Biotech:** The company has signed a definitive agreement with Aurigene Pharmaceutical Services for exclusive license of its proprietary biocatalytic technology for synthesis of Molnupiravir and supply its enzyme Candida Antarctica B Lipase to APSL, and APSL's exclusive procurement of the enzyme from the company.
- **Fedex Securities:** The company announced an open offer of upto 5,58,373 shares of face value Rs 10 each, representing 16.34% of the voting share capital.
- **Accel:** To buy 26% stake in Bizcarta Technologies India for up to Rs 5 crore.
- **Data Patterns India:** Wins Rs 27 crore order from DRDO.
- **Natco Pharma:** Pact with Medicines Patent Pool, Switzerland to make and sell Molnupiravir capsules.

### **Stocks Drop with Futures, Bonds Up as Nerves Fray**

U.S. equity futures declined and stocks fell Friday after a late-day reversal on Wall Street as sentiment skidded on some shaky company earnings reports and the prospect of tighter Federal Reserve policy. Contracts on the S&P 500 and technology-heavy Nasdaq 100 retreated, with the latter underperforming. Wall Street gains evaporated in a late-session reversal Thursday, marooning the tech gauge in a correction and leaving the S&P 500 off over 5% from its January high. MSCI Inc.'s Asia-Pacific equity index fell about 1%. Japan's Topix slid, bringing its drop from a September peak to some 10%. China and Hong Kong dipped. In China, the regulatory push against tech companies is again in focus. The nation vowed to curb their influence on governments. The tremors come as investors grapple with the prospect of reduced stimulus in the Fed's effort to quell high inflation. U.S. company developments also hit sentiment, with Netflix Inc. plunging on a disappointing subscriber outlook. A report that Washington is allowing some Baltic states to send U.S.-made weapons to Ukraine stoked concerns about a standoff with Russia. Treasury yields declined, the yen advanced and a dollar gauge fluctuated. Oil was lower on a surprise climb in U.S. crude stockpiles. The White House also said it can work to accelerate the release of strategic reserves.

### **Oil Extends Drop from Seven-Year High as U.S. Stockpiles Expand**

Oil extended its decline from the highest level since 2014 following a decline in U.S. stocks after a surprise gain in American crude inventories and a larger than expected increase in gasoline supplies. Futures in New York fell more than 3% in early Asian trading to below \$83 a barrel. Crude stockpiles rose for the first time in eight weeks, while gasoline supplies expanded by more than double the median forecast in a Bloomberg survey, according to government data. The White House also said it can work to accelerate the release of strategic oil reserves after prices rallied.

### **U.S. Hospital Crisis Eases; Hong Kong Ups Testing**

The U.S. hospital-staffing shortage exacerbated by the latest Covid-19 wave is showing signs of easing, but many West Coast and rural states are still seeing the worst of it. San Francisco's infections are falling rapidly from a peak a week and half ago. France will relax some restrictions early next month in a bet the pandemic will recede thanks to faster inoculations and plans to shut the unvaccinated out of most social activities. Austrian lawmakers passed the European Union's first law making coronavirus vaccinations mandatory. Hong Kong added 50 new locations including the airport, shopping district and one of the city's best-known noodle houses where mandatory tests are required for visitors to these sites. The sites are linked to an outbreak health officials believe started with pet hamsters.

### **Pharma Lobbying Hit Record as Democrats Took on Drug Pricing**

The main influence firm for drug makers spent a record amount lobbying last year, as Democrats attempted to pass legislation to allow the government to negotiate for better prices on medicines. The Pharmaceutical Research and Manufacturers of America spent nearly \$29.6 million on lobbying in 2021, the most the group has ever spent, according to federal disclosures filed Thursday. PhRMA wasn't alone: the Biotechnology Innovation Organization, which represents generic drug makers, spent nearly \$13.3 million in 2021, also a record for the group. The most PhRMA had previously spent on lobbying was \$28.9 million in 2019, according to federal disclosures. BIO spent \$12.5 million in 2020. Some individual drug makers also stepped up their lobbying spending in 2021. Eli Lilly & Co.'s \$7 million and Merck & Co.'s \$8 million were record amounts for both companies.

### Auto / Auto Ancillaries

[Porsche India sales grow 62 pc at 474 units in 2021](#)

[Toyota Kirloskar drives in Hilux brand; deliveries to begin in April](#)

[Hero MotoCorp commences bookings for next lot of XPulse 200 4 Valve](#)

[CESL invites bids for 5,580 e-buses](#)

[Domestic auto components industry to see 15-17 pc revenue growth this fiscal: Report](#)

[Ceat to prune and postpone investment in new plant due to tepid demand, eroding margins](#)

[India's market for luxury electric vehicles is hotting up](#)

[EVs are fast winning over the hesitant buyer. Better charging infra will accelerate it further](#)

### Banking & Finance

[Overnight call rate surges to 21-month high prompting RBI to act](#)

[Kotak Bank signs MoU with GIFT SEZ for boosting financial services ecosystem at IFSC](#)

[RBI approves Vinod Rai's appointment as independent chairman in Unity Bank](#)

[South Indian Bank cuts loss to Rs 50 crore](#)

[Magic of compounding; here is how you can grow your wealth](#)

[Y Combinator-backed Invoid joins Credenc, a Capital India company to build Neobank for students](#)

### Oil & Gas

[OPEC's share of Indian oil imports falls to lowest in at least 15 years](#)

[Vedanta to create \\$10 bln fund to bid for BPCL stake, other assets](#)

### Metals/Mining/Power

[Tata, Adani set to bid third time for UP Power Transco](#)

[ReNew Power, Fluence announce energy storage JV](#)

[Power sector employees to go on 2-day strike in Feb to protest privatisation: AIPEF](#)

[Fourth partner buys on-site solar assets of ReNew Power](#)

[India's mineral production up 5% in November 2021](#)

[SECL production crosses 100MT, co striving to achieve 172MT in FY22: Official](#)

### IT/Telecom/Media

[OneWeb counters Jio's claims of spectrum sale in Brazil](#)

[Which way 5G wind blows; significant shift in how telco operators engage with customers](#)

[Satcom companies will have a valid play in India; to complement telecom networks: Nelco CEO](#)

[STL claims patent infringement, HFCL to take legal recourse as court bars manufacturing, sales of multitube cable](#)

[Jio inks partnership with Finnish university to accelerate 6G research, standardization](#)

### FMCG/Retail/Textile/Food

[Videocon lenders invite fresh expressions of interest by Feb 2](#)

[GJEPC, MIDC sign draft agreement for setting up jewellery park](#)

[Unilever's strategy in spotlight after dropping \\$68 billion GSK battle](#)

[Lotus Herbals acquires 25% stake in D2C brand Conscious Chemist](#)

[Discretionary items' Republic Day sale parade marches on](#)

[Future mulls Supreme Court bid to avoid being named a defaulter - sources](#)

### Pharma/Fertilizers/Healthcare/Chemical

[Budget: Agrochem, pesticide sector urge govt to increase fund flow to the agri sector](#)

[Biophore India receives licences from MPP to market molnupiravir](#)

[Novo Nordisk launches anti-diabetes pill semaglutide in India](#)

[Two doses of Sputnik provide two times higher antibodies against Omicron than Pfizer vaccine: Study](#)

[Natco Pharma signs pact with MPP to sell Molnupiravir capsules](#)

[Zydus gets final US FDA nod to market generic version of Vigabatrin tablets](#)

### Infrastructure/Cement/Real Estate

[Larsen & Toubro dispatches coke drums to Mexico](#)

### Hospitality/Aviation/Logistics

[Aviation ministry may discuss 5G concerns with telecom department](#)

[NCLAT directs Jalan-Kalrock consortium to share resolution plan details with Jet Airways' workmen](#)

[5G row: Air India resumes 6 India-US flights on B777 aircraft after Boeing's clearance](#)

### **Analyst Certification:**

We /I, Jaydeb dey Research Analyst(s) and Shreyansh N. Mehta Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document



to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

---

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

---

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)

---